SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Neurocrine Biosciences Announces Q3 2026 Results Release Availability

NBIX
SquawkNews Desk 2 updates Updated Nov 02, 2026, 09:59 PM UTC

Story updates

09:51:25 PM UTC
SquawkNews
Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 202
09:59:10 PM UTC
SquawkNews
Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

Related stories

Apple CFO Sees Memory Purchase Pricing Continuing to Rise Apple’s CFO said memory purchase pricing is continuing to increase. L impact | EQUITY | Nov 02, 2026, 10:40 PM UTC Apple CFO Says Memory Purchase Prices Continue to Rise Apple's CFO said on a conference call that pricing for memory purchases continues to increase. M impact | EQUITY | Nov 02, 2026, 10:40 PM UTC Calix Q3 Revenue Rises, Issues Q4 Guidance Calix reported higher Q3 revenue and issued Q4 guidance. M impact | EQUITY | Nov 02, 2026, 10:40 PM UTC Ero Copper Reports Q3 Production of 18,345 Tonnes in Concentrate Ero Copper reported consolidated Q3 copper production of 18,345 tonnes in concentrate and C1 cash costs of $2.51 per pound. M impact | EQUITY | Nov 02, 2026, 10:39 PM UTC Apple Extends Extended-Hours Drop, Down 3.96% at $324.92 Apple shares were last down 3.96% at $324.92 in extended trading. M impact | EQUITY | Nov 02, 2026, 10:38 PM UTC Boise Cascade Reports Higher Q3 Earnings and Sales Boise Cascade reported that Q3 earnings and sales rose. M impact | EQUITY | Nov 02, 2026, 10:38 PM UTC